Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2010, Article ID 360136, 13 pages
http://dx.doi.org/10.1155/2010/360136
Review Article

Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?

1Department of Ocular Oncology, The Rotterdam Eye Hospital, The Netherlands
2Department of Clinical Genetics, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
3Department of Ophthalmology, Erasmus Medical Center, P.O. Box 70030, 3000 LM Rotterdam, The Netherlands

Received 23 December 2009; Accepted 15 March 2010

Academic Editor: Keith Hoek

Copyright © 2010 Thomas van den Bosch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Garbe and A. Blum, “Epidemiology of cutaneous melanoma in Germany and worldwide,” Skin Pharmacology and Applied Skin Physiology, vol. 14, no. 5, pp. 280–290, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. A.-V. Giblin and J. M. Thomas, “Incidence, mortality and survival in cutaneous melanoma,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 60, no. 1, pp. 32–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Nambiar, A. Mirmohammadsadegh, and U. R. Hengge, “Cutaneous melanoma: fishing with chips,” Current Molecular Medicine, vol. 8, no. 3, pp. 235–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. D. Singh, L. Bergman, and S. Seregard, “Uveal melanoma: epidemiologic aspects,” Ophthalmology Clinics of North America, vol. 18, no. 1, pp. 75–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Diener-West, B. S. Hawkins, J. A. Markowitz, and A. P. Schachat, “A review of mortality from choroidal melanoma: II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988,” Archives of Ophthalmology, vol. 110, no. 2, pp. 245–250, 1992. View at Google Scholar · View at Scopus
  6. J. W. Harbour, “Molecular prognostic testing and individualized patient care in uveal melanoma,” American Journal of Ophthalmology, vol. 148, no. 6, pp. 823–829, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Schmidt-Pokrzywniak, K.-H. Jöckel, N. Bornfeld, W. Sauerwein, and A. Stang, “Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study,” Ophthalmology, vol. 116, no. 2, pp. 340–348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Shields and S. C. Shields, Intraocular Tumors: An Atlas and Textbook, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2nd edition, 2007.
  9. K. D. Meyle and P. Guldberg, “Genetic risk factors for melanoma,” Human Genetics, vol. 126, no. 4, pp. 499–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. D. Singh, P. De Potter, B. A. Fijal, C. L. Shields, J. A. Shields, and R. C. Elston, “Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis,” Ophthalmology, vol. 105, no. 1, pp. 195–198, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Moan, A. C. Porojnicu, and A. Dahlback, “Ultraviolet radiation and malignant melanoma,” Advances in Experimental Medicine and Biology, vol. 624, pp. 104–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Saida, “Lessons learned from studies of the development of early melanoma,” International Journal of Clinical Oncology, vol. 10, no. 6, pp. 371–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. C. L. Shields, “The hunt for the secrets of uveal melanoma,” Clinical and Experimental Ophthalmology, vol. 36, no. 3, pp. 277–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Miller and M. C. Mihm Jr., “Melanoma,” The New England Journal of Medicine, vol. 355, no. 1, pp. 51–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Y. Bedikian, S. S. Legha, G. Mavligit et al., “Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors,” Cancer, vol. 76, no. 9, pp. 1665–1670, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Kujala, T. Mäkitie, and T. Kivelä, “Very long-term prognosis of patients with malignant uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 44, no. 11, pp. 4651–4659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Y. Bedikian, M. Millward, H. Pehamberger et al., “Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4738–4745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Tsao, M. B. Atkins, and A. J. Sober, “Management of cutaneous melanoma,” The New England Journal of Medicine, vol. 351, no. 10, pp. 998–1012, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. A. L. Vahrmeijer, C. J. H. van de Velde, H. H. Hartgrink, and R. A. E. M. Tollenaar, “Treatment of melanoma metastases confined to the liver and future perspectives,” Digestive Surgery, vol. 25, no. 6, pp. 467–472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Y. Bedikian, “Metastatic uveal melanoma therapy: current options,” International Ophthalmology Clinics, vol. 46, no. 1, pp. 151–166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Leiter, F. Meier, B. Schittek, and C. Garbe, “The natural course of cutaneous melanoma,” Journal of Surgical Oncology, vol. 86, no. 4, pp. 172–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. E. S. Gragoudas, K. M. Egan, J. M. Seddon et al., “Survival of patients with metastases from uveal melanoma,” Ophthalmology, vol. 98, no. 3, pp. 383–390, 1991. View at Google Scholar · View at Scopus
  23. M. D. Onken, L. A. Worley, and J. W. Harbour, “A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis,” Clinical Cancer Research, vol. 14, no. 12, pp. 3737–3745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. E. S. Gragoudas, “Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld lecture,” Investigative Ophthalmology and Visual Science, vol. 47, no. 11, pp. 4666–4673, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. K.V. Willson, D. M. Albert, M. Diener-West et al., “Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (coms) coms report no. 15,” Archives of Ophthalmology, vol. 119, no. 5, pp. 670–676, 2001. View at Google Scholar · View at Scopus
  26. M. Diener-West, S. M. Reynolds, D. J. Agugliaro et al., “Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2438–2444, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Landreville, O. A. Agapova, and J. W. Hartbour, “Emerging insights into the molecular pathogenesis of uveal melanoma,” Future Oncology, vol. 4, no. 5, pp. 629–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Eskelin, S. Pyrhönen, P. Summanen, M. Hahka-Kemppinen, and T. Kivelä, “Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment,” Ophthalmology, vol. 107, no. 8, pp. 1443–1449, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. C. L. Shields, J. A. Shields, H. Kiratli, P. De Potter, J. R. Cater, and I. W. McLean, “Risk factors for growth and metastasis of small choroidal melanocytic lesions,” Ophthalmology, vol. 102, no. 9, pp. 1351–1361, 1995. View at Google Scholar · View at Scopus
  30. C. L. Shields, J. Cater, J. A. Shields, A. D. Singh, M. C. M. Santos, and C. Carvalho, “Combination of clinical factors predictive of growth of small choroidal melanocytic tumors,” Archives of Ophthalmology, vol. 118, no. 3, pp. 360–364, 2000. View at Google Scholar · View at Scopus
  31. M. Diener-West, S. M. Reynolds, D. J. Agugliaro et al., “Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative Ocular Melanoma Study Group Report No. 26,” Archives of Ophthalmology, vol. 123, no. 12, pp. 1639–1643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Damato, “Legacy of the collaborative ocular melanoma study,” Archives of Ophthalmology, vol. 125, no. 7, pp. 966–968, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. D. Onken, L. A. Worley, J. P. Ehlers, and J. W. Harbour, “Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death,” Cancer Research, vol. 64, no. 20, pp. 7205–7209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Balch, A. C. Buzaid, S.-J. Soong et al., “New TNM melanoma staging system: linking biology and natural history to clinical outcomes,” Seminars in Surgical Oncology, vol. 21, no. 1, pp. 43–52, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. H. van Dekken, J. G. Pizzolo, V. E. Reuter, and M. R. Melamed, “Cytogenetic analysis of human solid tumors by in situ hybridization with a set of 12 chromosome-specific DNA probes,” Cytogenetics and Cell Genetics, vol. 54, no. 3-4, pp. 103–107, 1990. View at Google Scholar · View at Scopus
  36. B. J. Trask, “Fluorescence in situ hybridization: applications in cytogenetics and gene mapping,” Trends in Genetics, vol. 7, no. 5, pp. 149–154, 1991. View at Google Scholar · View at Scopus
  37. B. Damato, J. Dopierala, A. Klaasen, M. van Dijk, J. Sibbring, and S. E. Coupland, “Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death,” Investigative Ophthalmology & Visual Science, vol. 50, no. 7, pp. 3048–3055, 2009. View at Google Scholar · View at Scopus
  38. D. E. Horsman, H. Sroka, J. Rootman, and V. A. White, “Monosomy 3 and isochromosome 8q in a uveal melanoma,” Cancer Genetics and Cytogenetics, vol. 45, no. 2, pp. 249–253, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Prescher, N. Bornfeld, and R. Becher, “Nonrandom chromosomal abnormalities in primary uveal melanoma,” Journal of the National Cancer Institute, vol. 82, no. 22, pp. 1765–1769, 1990. View at Google Scholar · View at Scopus
  40. K. Sisley, I. G. Rennie, D. W. Cottam, A. M. Potter, C. W. Potter, and R. C. Rees, “Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8,” Genes Chromosomes and Cancer, vol. 2, no. 3, pp. 205–209, 1990. View at Google Scholar · View at Scopus
  41. A. G. M. Scholes, B. E. Damato, J. Nunn, P. Hiscott, I. Grierson, and J. K. Field, “Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival,” Investigative Ophthalmology and Visual Science, vol. 44, no. 3, pp. 1008–1011, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Höglund, D. Gisselsson, G. B. Hansen et al., “Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution,” International Journal of Cancer, vol. 108, no. 1, pp. 57–65, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. V. A. White, J. D. Chambers, P. D. Courtright, W. Y. Chang, and D. E. Horsman, “Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma,” Cancer, vol. 83, no. 2, pp. 354–359, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Prescher, N. Bornfeld, H. Hirche, B. Horsthemke, K.-H. Jöckel, and R. Becher, “Prognostic implications of monosomy 3 in uveal melanoma,” Lancet, vol. 347, no. 9010, pp. 1222–1225, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Sisley, I. G. Rennie, M. A. Parsons et al., “Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis,” Genes Chromosomes and Cancer, vol. 19, no. 1, pp. 22–28, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Sisley, M. A. Parsons, J. Garnham et al., “Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma,” British Journal of Cancer, vol. 82, no. 2, pp. 330–338, 2000. View at Google Scholar · View at Scopus
  47. B. Horsthemke, G. Prescher, N. Bornfeld, and R. Becher, “Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma,” Genes Chromosomes and Cancer, vol. 4, no. 3, pp. 217–221, 1992. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Aalto, L. Eriksson, S. Seregard, O. Larsson, and S. Knuutila, “Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 42, no. 2, pp. 313–317, 2001. View at Google Scholar · View at Scopus
  49. G. Prescher, N. Bornfeld, W. Friedrichs, S. Seeber, and R. Becher, “Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation,” Cancer Genetics and Cytogenetics, vol. 80, no. 1, pp. 40–46, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. M. D. Onken, L. A. Worley, E. Person, D. H. Char, A. M. Bowcock, and J. W. Harbour, “Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma,” Clinical Cancer Research, vol. 13, no. 10, pp. 2923–2927, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Parrella, V. M. Fazio, A. P. Gallo, D. Sidransky, and S. L. Merbs, “Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2,” Cancer Research, vol. 63, no. 23, pp. 8507–8510, 2003. View at Google Scholar · View at Scopus
  52. F. Tschentscher, J. Hüsing, T. Hölter et al., “Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities,” Cancer Research, vol. 63, no. 10, pp. 2578–2584, 2003. View at Google Scholar · View at Scopus
  53. W. van Gils, E. M. Lodder, H. W. Mensink et al., “Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis,” Investigative Ophthalmology and Visual Science, vol. 49, no. 10, pp. 4254–4262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. M. D. Onken, J. P. Ehlers, L. A. Worley, J. Makita, Y. Yokota, and J. W. Harbour, “Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas,” Cancer Research, vol. 66, no. 9, pp. 4602–4609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. L. A. Worley, M. D. Onken, E. Person et al., “Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma,” Clinical Cancer Research, vol. 13, no. 5, pp. 1466–1471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. U. Petrausch, P. Martus, H. Tönnies et al., “Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases,” Eye, vol. 22, no. 8, pp. 997–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. D. E. Horsman and V. A. White, “Cytogenetic analysis of uveal melanoma: consistent occurrence of monosomy 3 and trisomy 8q,” Cancer, vol. 71, no. 3, pp. 811–819, 1993. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Kilic, W. van Gils, E. Lodder et al., “Clinical and cytogenetic analyses in uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 47, no. 9, pp. 3703–3707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Sisley, N. Tattersall, M. Dyson, K. Smith, H. S. Mudhar, and I. G. Rennie, “Multiplex fluorescence in situ hybridization identifies novel rearrangements of chromosomes 6, 15, and 18 in primary uveal melanoma,” Experimental Eye Research, vol. 83, no. 3, pp. 554–559, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Hughes, B. E. Damato, I. Giddings, P. S. Hiscott, J. Humphreys, and R. S. Houlston, “Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3,” British Journal of Cancer, vol. 93, no. 10, pp. 1191–1196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Parrella, O. L. Caballero, D. Sidransky, and S. L. Merbs, “Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization,” Investigative Ophthalmology and Visual Science, vol. 42, no. 8, pp. 1679–1684, 2001. View at Google Scholar · View at Scopus
  62. J. P. Ehlers and J. W. Harbour, “NBS1 expression as a prognostic marker in uveal melanoma,” Clinical Cancer Research, vol. 11, no. 5, pp. 1849–1853, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. J. P. Ehlers, L. Worley, M. D. Onken, and J. W. Harbour, “DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma,” Clinical Cancer Research, vol. 11, no. 10, pp. 3609–3613, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. B. Amati, K. Alevizopoulos, and J. Vlach, “Myc and the cell cycle,” Frontiers in Bioscience, vol. 3, pp. D250–D268, 1998. View at Google Scholar
  65. E. Kilic, N. C. Naus, W. van Gils et al., “Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients,” Investigative Ophthalmology and Visual Science, vol. 46, no. 7, pp. 2253–2257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. W. van Gils, H. W. Mensink, E. Kilic et al., “Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 48, no. 11, pp. 4919–4923, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Häusler, A. Stang, G. Anastassiou et al., “Loss of heterozygosity of 1p in uveal melanomas with monosomy 3,” International Journal of Cancer, vol. 116, no. 6, pp. 909–913, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Parrella, D. Sidransky, and S. L. Merbs, “Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway,” Cancer Research, vol. 59, no. 13, pp. 3032–3037, 1999. View at Google Scholar · View at Scopus
  69. J. P. Ehlers and J. W. Harbour, “Molecular pathobiology of uveal melanoma,” International Ophthalmology Clinics, vol. 46, no. 1, pp. 167–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Ghazvini, D. H. Char, S. Kroll, F. M. Waldman, and D. Pinkel, “Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas,” Cancer Genetics and Cytogenetics, vol. 90, no. 2, pp. 95–101, 1996. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Papp, H. Pemsel, R. Zimmermann, R. Bastrop, D. G. Weiss, and D. Schiffmann, “Mutational analysis of the N-ras, p53, p16(INK4a), CDK4, and MC1R genes in human congenital melanocytic naevi,” Journal of Medical Genetics, vol. 36, no. 8, pp. 610–614, 1999. View at Google Scholar · View at Scopus
  72. A. Demunter, M. Stas, H. Degreef, C. De Wolf-Peeters, and J. J. van den Oord, “Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma,” Journal of Investigative Dermatology, vol. 117, no. 6, pp. 1483–1489, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. J. M. Stahl, A. Sharma, M. Cheung et al., “Deregulated Akt3 activity promotes development of malignant melanoma,” Cancer Research, vol. 64, no. 19, pp. 7002–7010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. P. M. Pollock and P. S. Meltzer, “A genome-based strategy uncovers frequent BRAF mutations in melanoma,” Cancer Cell, vol. 2, no. 1, pp. 5–7, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. V. R. Greene, M. M. Johnson, E. A. Grimm, and J. A. Ellerhorst, “Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma,” Journal of Investigative Dermatology, vol. 129, no. 6, pp. 1483–1488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Meyer, H. Stapelmann, B. Frank et al., “Molecular genetic analysis of NBS1 in German melanoma patients,” Melanoma Research, vol. 17, no. 2, pp. 109–116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. G. M. Kraehn, J. Utikal, M. Udart et al., “Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases,” British Journal of Cancer, vol. 84, no. 1, pp. 72–79, 2001. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Treszl, R. Ádány, Z. Rákosy et al., “Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation,” Cytometry Part B, vol. 60, no. 1, pp. 37–46, 2004. View at Google Scholar · View at Scopus
  80. M. Stark and N. Hayward, “Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays,” Cancer Research, vol. 67, no. 6, pp. 2632–2642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. C. D. van Raamsdonk, V. Bezrookove, G. Green et al., “Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi,” Nature, vol. 457, no. 7229, pp. 599–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. J. A. Curtin, J. Fridlyand, T. Kageshita et al., “Distinct sets of genetic alterations in melanoma,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2135–2147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Jönsson, C. Dahl, J. Staaf et al., “Genomic profiling of malignant melanoma using tiling-resolution arrayCGH,” Oncogene, vol. 26, no. 32, pp. 4738–4748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. E. R. Sauter, U.-C. Yeo, A. Von Stemm et al., “Cyclin D1 is a candidate oncogene in cutaneous melanoma,” Cancer Research, vol. 62, no. 11, pp. 3200–3206, 2002. View at Google Scholar · View at Scopus
  85. N. Ibrahim and F. G. Haluska, “Molecular pathogenesis of cutaneous melanocytic neoplasms,” Annual Review of Pathology, vol. 4, pp. 551–579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. B. Jansen, H. Schlagbauer-Wadl, B. D. Brown et al., “BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice,” Nature Medicine, vol. 4, no. 2, pp. 232–234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Pons, P. Mancheño-Corvo, P. Martín-Duque, and M. Quintanilla, “Molecular biology of malignant melanoma,” Advances in Experimental Medicine and Biology, vol. 624, pp. 252–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. D. E. Quelle, F. Zindy, R. A. Ashmun, and C. J. Sherr, “Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest,” Cell, vol. 83, no. 6, pp. 993–1000, 1995. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Kamb, N. A. Gruis, J. Weaver-Feldhaus et al., “A cell cycle regulator potentially involved in genesis of many tumor types,” Science, vol. 264, no. 5157, p. 436, 1994. View at Google Scholar · View at Scopus
  90. N. E. Sharpless and L. Chin, “The INK4a/ARF locus and melanoma,” Oncogene, vol. 22, no. 20, pp. 3092–3098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. A. M. Goldstein, M. Chan, M. Harland et al., “Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents,” Journal of Medical Genetics, vol. 44, no. 2, pp. 99–106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Wu, V. Goel, and F. G. Haluska, “PTEN signaling pathways in melanoma,” Oncogene, vol. 22, no. 20, pp. 3113–3122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Tsao, X. Zhang, E. Benoit, and F. G. Haluska, “Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines,” Oncogene, vol. 16, no. 26, pp. 3397–3402, 1998. View at Google Scholar · View at Scopus
  94. H. Tsao, X. Zhang, K. Fowlkes, and F. G. Haluska, “Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines,” Cancer Research, vol. 60, no. 7, pp. 1800–1804, 2000. View at Google Scholar · View at Scopus
  95. C. M. Mooy, M. J. van der Helm, T. H. van der Kwast, P. T. V. M. De Jong, D. J. Ruiter, and E. C. Zwarthoff, “No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited,” British Journal of Cancer, vol. 64, no. 2, pp. 411–413, 1991. View at Google Scholar · View at Scopus
  96. E. Kiliç, H. T. Brüggenwirth, M. M. P. J. Verbiest et al., “The RAS-BRAF kinase pathway is not involved in uveal melanoma,” Melanoma Research, vol. 14, no. 3, pp. 203–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Saldanha, D. Purnell, A. Fletcher, L. Potter, A. Gillies, and J. H. Pringle, “High BRAF mutation frequency does not characterize all melanocytic tumor types,” International Journal of Cancer, vol. 111, no. 5, pp. 705–710, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. C. S. Janssen, R. Sibbett, F. L. Henriquez, I. C. McKay, E. G. Kemp, and F. Roberts, “The T1799A point mutation is present in posterior uveal melanoma,” British Journal of Cancer, vol. 99, no. 10, pp. 1673–1677, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. Cohen, N. Goldenberg-Cohen, P. Parrella et al., “Lack of BRAF mutation in primary uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 44, no. 7, pp. 2876–2878, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. F. Henriquez, C. Janssen, E. G. Kemp, and F. Roberts, “The T1799A BRAF mutation is present in iris melanoma,” Investigative Ophthalmology and Visual Science, vol. 48, no. 11, pp. 4897–4900, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. H. E. Spendlove, B. E. Damato, J. Humphreys, K. T. Barker, P. S. Hiscott, and R. S. Houlston, “BRAF mutations are detectable in conjunctival but not uveal melanomas,” Melanoma Research, vol. 14, no. 6, pp. 449–452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Falck, J. H. J. Petrini, B. R. Williams, J. Lukas, and J. Bartek, “The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways,” Nature Genetics, vol. 30, no. 3, pp. 290–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Parrella, O. L. Caballero, D. Sidransky, and S. L. Merbs, “Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization,” Investigative Ophthalmology and Visual Science, vol. 42, no. 8, pp. 1679–1684, 2001. View at Google Scholar · View at Scopus
  104. J. Bauer, E. Kilic, J. Vaarwater, B. C. Bastian, C. Garbe, and A. De Klein, “Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma,” British Journal of Cancer, vol. 101, no. 5, pp. 813–815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. M. A. Brantley Jr. and J. W. Harbour, “Deregulation of the Rb and p53 pathways in uveal melanoma,” American Journal of Pathology, vol. 157, no. 6, pp. 1795–1801, 2000. View at Google Scholar · View at Scopus
  106. S. E. Coupland, G. Anastassiou, A. Stang et al., “The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma,” Journal of Pathology, vol. 191, no. 2, pp. 120–126, 2000. View at Publisher · View at Google Scholar · View at Scopus
  107. S. E. Coupland, N. Bechrakis, A. Schüler et al., “Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma,” British Journal of Ophthalmology, vol. 82, no. 8, pp. 961–970, 1998. View at Google Scholar · View at Scopus
  108. J. S. Ghana, G. D. Wilson, I. A. Cree et al., “c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma,” British Journal of Ophthalmology, vol. 83, no. 1, pp. 110–114, 1999. View at Google Scholar · View at Scopus
  109. V. Jay, Q. Yi, W. S. Hunter, and M. Zielenska, “Expression of bcl-2 in uveal malignant melanoma,” Archives of Pathology and Laboratory Medicine, vol. 120, no. 5, pp. 497–498, 1996. View at Google Scholar · View at Scopus
  110. A. D. Singh, M. X. Wang, L. A. Donoso, C. L. Shields, P. De Potter, and J. A. Shields, “Genetic aspects of uveal melanoma: a brief review,” Seminars in Oncology, vol. 23, no. 6, pp. 768–772, 1996. View at Google Scholar · View at Scopus
  111. J. P. Ehlers, L. Worley, M. D. Onken, and J. W. Harbour, “Integrative genomic analysis of aneuploidy in uveal melanoma,” Clinical Cancer Research, vol. 14, no. 1, pp. 115–122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. M. H. Abdel-Rahman, Y. Yang, X.-P. Zhou, E. L. Craig, F. H. Davidorf, and C. Eng, “High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma,” Journal of Clinical Oncology, vol. 24, no. 2, pp. 288–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. P. T. C. Wan, M. J. Garnett, S. M. Roe et al., “Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF,” Cell, vol. 116, no. 6, pp. 855–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. P. A. Randazzo, J. Andrade, K. Miura et al., “The Arf GTPase-activating protein ASAP1 regulates the actin cytoskeleton,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4011–4016, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. Y. Liu, J. C. Loijens, K. H. Martin, A. V. Karginov, and J. T. Parsons, “The association of ASAP1, an ADP ribosylation factor-GTPase activating protein, with focal adhesion kinase contributes to the process of focal adhesion assembly,” Molecular Biology of the Cell, vol. 13, no. 6, pp. 2147–2156, 2002. View at Publisher · View at Google Scholar · View at Scopus
  116. G. G. McGill, M. Horstmann, H. R. Widlund et al., “Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability,” Cell, vol. 109, no. 6, pp. 707–718, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Wellbrock, M. Karasarides, and R. Marais, “The RAF proteins take centre stage,” Nature Reviews Molecular Cell Biology, vol. 5, no. 11, pp. 875–885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Platz, S. Egyhazi, U. Ringborg, and J. Hansson, “Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site,” Molecular Oncology, vol. 1, no. 4, pp. 395–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. J. C. Chuang and P. A. Jones, “Epigenetics and microRNAs,” Pediatric Research, vol. 61, no. 5, part 2, pp. 24R–29R, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. S. L. Merbs and D. Sidransky, “Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 40, no. 3, pp. 779–783, 1999. View at Google Scholar · View at Scopus
  121. P. A. van der Veiden, J. A. W. Metzelaar-Blok, W. Bergman et al., “Promoter hypermethylation: a common cause of reduced p16INK4a expression in uveal melanoma,” Cancer Research, vol. 61, no. 13, pp. 5303–5306, 2001. View at Google Scholar · View at Scopus
  122. W. Maat, P. A. van der Velden, C. Out-Luiting et al., “Epigenetic inactivation of RASSF1a in uveal melanoma,” Investigative Ophthalmology and Visual Science, vol. 48, no. 2, pp. 486–490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. A. P. Moulin, G. Clément, F. T. Bosman, L. Zografos, and J. Benhattar, “Methylation of CpG island promoters in uveal melanoma,” British Journal of Ophthalmology, vol. 92, no. 2, pp. 281–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. L. A. Worley, M. D. Long, M. D. Onken, and J. W. Harbour, “Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling,” Melanoma Research, vol. 18, no. 3, pp. 184–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Radhakrishnan, N. Badhrinarayanan, J. Biswas, and S. Krishnakumar, “Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma,” Molecular Vision, vol. 15, pp. 2146–2154, 2009. View at Google Scholar · View at Scopus
  126. L. T. Bemis, R. Chen, C. M. Amato et al., “MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines,” Cancer Research, vol. 68, no. 5, pp. 1362–1368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. M. F. Segura, D. Hanniford, S. Menendez et al., “Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 6, pp. 1814–1819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. F. Felicetti, M. C. Errico, P. Segnalini, G. Mattia, and A. Carè, “MicroRNA-221 and -222 pathway controls melanoma progression,” Expert Review of Anticancer Therapy, vol. 8, no. 11, pp. 1759–1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. S. M. Johnson, H. Grosshans, J. Shingara et al., “RAS is regulated by the let-7 microRNA family,” Cell, vol. 120, no. 5, pp. 635–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
  130. A. D. Singh and A. Topham, “Survival rates with uveal melanoma in the United States: 1973–1997,” Ophthalmology, vol. 110, no. 5, pp. 962–965, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. C. L. Shields, A. Ganguly, M. A. Materin et al., “Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship,” Archives of Ophthalmology, vol. 125, no. 8, pp. 1017–1024, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. E. Midena, L. Bonaldi, R. Parrozzani, E. Tebaldi, B. Boccassini, and S. Vujosevic, “In vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy,” European Journal of Ophthalmology, vol. 16, no. 3, pp. 422–425, 2006. View at Google Scholar · View at Scopus
  133. T. A. Young, N. P. Rao, B. J. Glasgow, J. N. Moral, and B. R. Straatsma, “Fluorescent in situ hybridization of monosomy 3 via 30-gauge fine-needles aspiration biopsy of choroidal melanoma in vivo,” Ophthalmology, vol. 114, no. 1, pp. 142–146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. C. L. Shields, M. A. Materin, L. Teixeira, A. Mashayekhi, A. Ganguly, and J. A. Shields, “Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy,” Ophthalmology, vol. 114, no. 10, pp. 1919–1924, 2007. View at Publisher · View at Google Scholar · View at Scopus